CRTD (Creatd Inc.) Sells Remaining 80% of Fly Flyte to NYSE-Listed VTAK (Catheter Precision Inc.), Securing Significant Cash and Equity Position
MWN-AI** Summary
On March 10, 2026, Creatd, Inc. (OTCQB: CRTDD) announced the successful sale of its remaining 80% equity stake in Fly Flyte, Inc. to Catheter Precision, Inc. (NYSE American: VTAK). The transaction is valued at approximately $12 million, consisting of about $6 million in cash and an equal amount in Convertible Preferred Stock of VTAK. This strategic move significantly enhances Creatd's balance sheet and aligns with its approach of preparing businesses for public market listings while retaining minority ownership.
Having acquired Flyte approximately a year ago, Creatd implemented a turnaround strategy aimed at operational improvement and technology integration, facilitating the subsidiary’s eventual acquisition by a larger, publicly traded company. The cash infusion and preferred equity from VTAK will support Creatd's future strategy of pursuing a listing on a national exchange while cultivating its portfolio across diverse sectors supported by high-tech infrastructure.
Jeremy Frommer, Chairman and CEO of Creatd, emphasized that the company aims to create value through acquisition and incubation strategies for exchange-listed entities. He stated their model intends to help companies stabilize, grow, and achieve national exchange listings without relying on conventional financing structures that often hinder growth.
Furthermore, the relationship between Creatd and VTAK will persist as both entities collaborate on developing aviation and eVTOL (electric Vertical Take-Off and Landing) logistics solutions. As Creatd continues its transformation and expansion, it aims to address gaps in the middle market by providing support for public companies seeking to optimize their infrastructures for long-term success.
MWN-AI** Analysis
Creatd, Inc. (OTCQB: CRTDD) has made headway in its strategic pivot by selling its remaining 80% stake in Fly Flyte, Inc. to Catheter Precision, Inc. (NYSE American: VTAK). The transaction, valued at approximately $12 million in cash and convertible preferred stock, reinforces Creatd’s balance sheet and positions it as a significant shareholder in a publicly listed entity. This maneuver aligns with Creatd's overarching strategy of incubating and preparing companies for successful public listings while retaining minority interests for potential future growth.
The sale has effectively polarized investor sentiment, reflecting optimism regarding Creatd’s capacity for capital growth. The receipt of funds allows Creatd to further its ambition to list on a national exchange, primarily through a model that avoids traditional financing methods, which often dilute existing shareholder value. This strategy is particularly notable given the current climate of contraction in the middle market, where many public companies struggle with infrastructural gaps. Creatd’s comprehensive operational support could provide a lifeline for these businesses, supporting their development into viable national contenders.
Investors should monitor Creatd’s execution of this strategy closely. The transition to rely on a portfolio of public and private equity positions, combined with its AI-first operational infrastructure, positions the company favorably to attract institutional interest. The potential upside from its equity in VTAK is significant, as healthcare-related investments—especially those publicly traded—can experience robust growth dynamics.
As Creatd continues to execute on its transformation plan, shaped by diligent acquisition efforts and enhanced by the strategic divestiture of Fly Flyte, the market may see elevated investor interest. Potential investors should consider both the inherent risks involved in small-cap transformations and the opportunities for substantial gains facilitated by Creatd's strategic positioning and operational prowess.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB: CRTDD) today announced that it has sold its remaining 80% equity stake in its subsidiary, Fly Flyte, Inc. (“Flyte”), to Catheter Precision, Inc. (NYSE American: VTAK). Under the terms of the completed transaction, Creatd will receive approximately $6,000,000 in cash and nearly $6,000,000 in Convertible Preferred Stock of VTAK. The NYSE-approved transaction considerably strengthens Creatd’s balance sheet.
The sale is consistent with Creatd’s strategy of developing turnkey operating solutions that prepare businesses for listing on the public markets while simultaneously retaining a minority interest in them. The transaction positions Creatd as a significant shareholder in VTAK.
The NYSE-listed VTAK equity becomes part of Creatd’s growing portfolio of public and private positions across diversified industries, supported by its technology and AI-first operational infrastructure. Creatd helps companies overcome structural hurdles and mature into institutionally viable enterprises.
Creatd acquired Flyte approximately one year ago, after initiating due diligence in Q4 2024, and implemented a disciplined turnaround strategy built around operational optimization, technology integration, and targeted revenue growth, while positioning the company for acquisition by a nationally-listed platform.
Creatd initially acquired its position in Flyte using a combination of financing and its then OTC Pink Sheet common stock, whereas the premium exit consideration consists of cash and preferred equity in a New York Stock Exchange-listed company.
“Creatd will continue to pursue its own national exchange listing strategy this year. The plan is to do so without relying on the traditional financing structures that often accompany those transactions. Typically those structures consume companies that have not first generated their own balance sheet value,” said Jeremy Frommer, Chairman and CEO of Creatd, Inc. “Our recent reverse split, completed without an accompanying financing, was an important step toward meeting those national exchange listing requirements. This asset sale now provides the capital needed to complete the next phase.”
“Our balance sheet value is created through acquisition and incubation strategies for exchange-listed entities, where operating businesses can develop and position themselves for long term success. At the same time, Creatd is building value from a portfolio of investments that leverage proprietary technology and process.”
“Creatd represents one of the few turnaround-focused publicly traded platforms in the small-cap and micro-cap M&A space. We intend to institutionalize this model as we expand and broaden our company’s platform,” continued Frommer.
“We also see a significant opportunity to address the structural gap created by the contraction of the middle market over the past two decades. Too many public companies today lack the infrastructure and support needed to reach their full potential. We are building a platform that helps companies stabilize, scale, and ultimately reach national exchange listings while creating lasting value.”
Creatd and VTAK will continue to collaborate through their strategic relationship, including ongoing efforts in aviation and eVTOL logistics platform development. The Company is grateful for the continued support of its shareholders throughout its multi-year transition and remains focused on executing its plan.
About Creatd:
Creatd, Inc. (OTCQB: CRTDD) acquires and grows technology-driven companies in aviation, media, and advisory services. Through its shared services model, Creatd enables its portfolio companies to scale efficiently, improve margins, and expand market reach. For more information, visit www.creatd.com.
About Flyte:
Flyte is a technology-enabled regional air mobility company operating a growing fleet of Cirrus Vision Jets. Focused on high frequency, short haul markets, Flyte provides a faster, safer, and more efficient alternative to traditional private charter.
Flight operations are conducted through Flyte’s related entity, Ponderosa Air, LLC, an FAA certified Part 135 air carrier. With certified aircraft, active revenue generating operations, and scalable fleet expansion underway, Flyte is building disciplined, asset backed aviation infrastructure designed to serve underserved regional markets.
For more information, visit: www.flyte.travel
Contact: ir@creatd.com
Forward-Looking Statements:
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements include all statements, other than statements of historical fact, regarding our current views and assumptions with respect to future events regarding our business and our expectations with respect to the completion of the offering, the satisfaction of customary closing conditions related to the offering and the additional closings, the anticipated use of proceeds therefrom, and other statements that are predictive in nature. These statements can be identified often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “intends,” “plans,” “believes” and “projects,” and may involve estimates and uncertainties which could cause actual results to differ materially from those expressed in the forward-looking statements. We caution that the factors described herein could cause actual results to differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Such factors and risks include, among others, market and other risks, that the additional closings after today may not occur if certain closing conditions are not met, and that there can be no assurance that the Company will successfully uplist to a national securities exchange. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. This press release contains forward-looking statements and is qualified in its entirety by, and should be read together with, the cautionary statements, risk factors and other disclosures contained in the Company’s filings with the SEC and OTC Markets.
Source: CREATD INC.
FAQ**
How will the acquisition of Fly Flyte, Inc. by Catheter Precision, Inc. (VTAK) impact Creatd's overall financial strategy and investment portfolio in the long term?
What potential synergies do Creatd, Inc. foresee between their business model and Catheter Precision Inc. (VTAK) as a major shareholder in the latter?
What steps is Creatd taking to ensure the successful integration of Flyte's operations with Catheter Precision Inc. (VTAK) and harness its growth potential moving forward?
Can you elaborate on how the collaboration between Creatd and Catheter Precision Inc. (VTAK) in aviation will enhance the operational capabilities of Flyte?
**MWN-AI FAQ is based on asking OpenAI questions about Catheter Precision Inc. (NYSE: VTAK).
NASDAQ: VTAK
VTAK Trading
35.81% G/L:
$1.8878 Last:
54,556,101 Volume:
$2.02 Open:
